Company: NCEL
Filing Date: 2025-03-10
Form Type: 425
Source: 0001213900-25-021979
Chunk: 5

Company: NewcelX Ltd.
Filing Date: 2025-03-10
Form: 425
Chunk 5
---
 uncertainties related to
the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties related to the failure to timely,
or at all, obtain shareholder approvals for the transaction; unexpected costs, charges or expenses resulting from the transaction and
potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Merger; changes
in technology and market requirements; either or both companies may encounter delays or obstacles in launching and/or successfully completing
their clinical trials; the companies’ products may not be approved by regulatory agencies; their technologies may not be validated
as they progress and their methods may not be accepted by the scientific community; either of both of the companies may be unable to retain
or attract key employees whose knowledge is essential to the development of their products; unforeseen scientific difficulties may develop
with the products being advanced by the companies; their products may wind up being more expensive than anticipated; results in the laboratory
may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results
of human clinical trials; the companies’ patents may not be sufficient; their products may harm recipients; changes in legislation
may adversely impact either or both of the companies; inability to timely develop and introduce new technologies, products and applications;
and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of candidate
products to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, neither
Kadimastem nor NLS undertakes any obligation to publicly release any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and
uncertainties affecting NLS is contained under the heading “Risk Factors” in NLS’s annual report on Form 20-F for the
year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”), which is available on the SEC’s
website, www.sec.gov, and in subsequent filings made by NLS with the SEC, including under the heading “Risk Factors” in NLS’s
registration statement on Form F-4, filed with the SEC on December 27, 2024.

No Offer or Solicitation

This communication is not intended to and shall
not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote